DDI-DrugBank.d659.s0 >> Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. >> 152-158,177-190,195-225
DDI-DrugBank.d659.s1 >> Patients on Warfarin should have more frequent monitoring of prothrombin times, while patients with other risk factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should have periodic examinations for bleeding including hematocrit and/or hemoglobin. >> 12-19
DDI-DrugBank.d659.s2 >> Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. >> 30-36,42-53,91-102,115-126
DDI-DrugBank.d659.s3 >> Such patients should be closely monitored for signs of toxicity and have their theophylline dosage adjusted as necessary. >> 79-90
DDI-DrugBank.d659.s4 >> TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. >> 0-6,40-61,64-76,79-87,90-98,101-119,126-140
DDI-DrugBank.d659.s5 >> Small decreases in blood pressure have been observed in some patients treated with TRENTAL; >> 83-89
DDI-DrugBank.d659.s6 >> periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy.
DDI-DrugBank.d659.s7 >> If indicated, dosage of the antihypertensive agents should be reduced. >> 28-50
